Published in Antimicrob Agents Chemother on March 01, 1999
Pharmacodynamics of fluoroquinolones against Streptococcus pneumoniae in patients with community-acquired respiratory tract infections. Antimicrob Agents Chemother (2001) 2.23
Pharmacodynamic functions: a multiparameter approach to the design of antibiotic treatment regimens. Antimicrob Agents Chemother (2004) 1.93
In vitro pharmacodynamic evaluation of the mutant selection window hypothesis using four fluoroquinolones against Staphylococcus aureus. Antimicrob Agents Chemother (2003) 1.92
Activities of moxifloxacin against, and emergence of resistance in, Streptococcus pneumoniae and Pseudomonas aeruginosa in an in vitro pharmacokinetic model. Antimicrob Agents Chemother (2003) 1.37
Quinolone efflux pumps play a central role in emergence of fluoroquinolone resistance in Streptococcus pneumoniae. Antimicrob Agents Chemother (2006) 1.26
Pharmacodynamic assessment of gatifloxacin against Streptococcus pneumoniae. Antimicrob Agents Chemother (2001) 1.25
Pharmacodynamics of levofloxacin and ciprofloxacin in a murine pneumonia model: peak concentration/MIC versus area under the curve/MIC ratios. Antimicrob Agents Chemother (2003) 1.17
Pharmacokinetic/pharmacodynamic (PK/PD) indices of antibiotics predicted by a semimechanistic PKPD model: a step toward model-based dose optimization. Antimicrob Agents Chemother (2011) 1.12
Mutant selection window in levofloxacin and moxifloxacin treatments of experimental pneumococcal pneumonia in a rabbit model of human therapy. Antimicrob Agents Chemother (2004) 1.08
Comparative bactericidal activities of ciprofloxacin, clinafloxacin, grepafloxacin, levofloxacin, moxifloxacin, and trovafloxacin against Streptococcus pneumoniae in a dynamic in vitro model. Antimicrob Agents Chemother (2001) 1.04
Novel murine model of pneumococcal pneumonia: use of temperature as a measure of disease severity to compare the efficacies of moxifloxacin and levofloxacin. Antimicrob Agents Chemother (2004) 0.99
Pharmacodynamics of gemifloxacin against Streptococcus pneumoniae in an in vitro pharmacokinetic model of infection. Antimicrob Agents Chemother (2001) 0.98
In vitro infection model characterizing the effect of efflux pump inhibition on prevention of resistance to levofloxacin and ciprofloxacin in Streptococcus pneumoniae. Antimicrob Agents Chemother (2007) 0.94
Worldwide antimicrobial susceptibility patterns and pharmacodynamic comparisons of gatifloxacin and levofloxacin against Streptococcus pneumoniae: report from the Antimicrobial Resistance Rate Epidemiology Study Team. Antimicrob Agents Chemother (2003) 0.94
Levofloxacin pharmacokinetics and pharmacodynamics in patients with severe burn injury. Antimicrob Agents Chemother (2006) 0.92
Pharmacodynamics of gatifloxacin against Streptococcus pneumoniae in an in vitro pharmacokinetic model: impact of area under the curve/MIC ratios on eradication. Antimicrob Agents Chemother (2002) 0.92
Pharmacodynamics of trovafloxacin and levofloxacin against Bacteroides fragilis in an in vitro pharmacodynamic model. Antimicrob Agents Chemother (2002) 0.91
Pharmacodynamics of a novel des-F(6)-quinolone, BMS-284756, against Streptococcus pneumoniae in the thigh infection model. Antimicrob Agents Chemother (2003) 0.90
Factors influencing fluoroquinolone resistance. Emerg Infect Dis (2003) 0.88
Pharmacodynamic assessment based on mutant prevention concentrations of fluoroquinolones to prevent the emergence of resistant mutants of Streptococcus pneumoniae. Antimicrob Agents Chemother (2007) 0.86
Pharmacokinetic-pharmacodynamic relationships describing the efficacy of oritavancin in patients with Staphylococcus aureus bacteremia. Antimicrob Agents Chemother (2006) 0.86
Pharmacokinetics of levofloxacin and ciprofloxacin during continuous renal replacement therapy in critically ill patients. Antimicrob Agents Chemother (2001) 0.86
Pharmacokinetics of ciprofloxacin and its penetration into bronchial secretions of mechanically ventilated patients with chronic obstructive pulmonary disease. Antimicrob Agents Chemother (2011) 0.85
Influence of Pharmacokinetic and Pharmacodynamic Principles on Antibiotic Selection. Curr Infect Dis Rep (2001) 0.83
Pharmacodynamics of moxifloxacin and levofloxacin at simulated epithelial lining fluid drug concentrations against Streptococcus pneumoniae. Antimicrob Agents Chemother (2004) 0.83
Levofloxacin disposition in cerebrospinal fluid in patients with external ventriculostomy. Antimicrob Agents Chemother (2003) 0.83
Population pharmacokinetics and pharmacodynamics of garenoxacin in patients with community-acquired respiratory tract infections. Antimicrob Agents Chemother (2004) 0.82
Mechanism of fluoroquinolone resistance is an important factor in determining the antimicrobial effect of gemifloxacin against Streptococcus pneumoniae in an in vitro pharmacokinetic model. Antimicrob Agents Chemother (2003) 0.81
Duration of antimicrobial therapy in community acquired pneumonia: less is more. ScientificWorldJournal (2014) 0.78
Small-plasmid-mediated antibiotic resistance is enhanced by increases in plasmid copy number and bacterial fitness. Antimicrob Agents Chemother (2015) 0.78
Modeling in vivo pharmacokinetics and pharmacodynamics of moxifloxacin therapy for Mycobacterium tuberculosis infection by using a novel cartridge system. Antimicrob Agents Chemother (2005) 0.78
A Novel Metallo-β-Lactamase Involved in the Ampicillin Resistance of Streptococcus pneumoniae ATCC 49136 Strain. PLoS One (2016) 0.75
A naturally occurring SNP in plasmid pB1000 produces a reversible increase in antibiotic resistance. Antimicrob Agents Chemother (2016) 0.75
Pharmacokinetic and Pharmacodynamic Principles of Anti-infective Dosing. Clin Ther (2016) 0.75
Moxifloxacin pharmacokinetic profile and efficacy evaluation in empiric treatment of community-acquired pneumonia. Antimicrob Agents Chemother (2015) 0.75
Pharmacodynamics of intravenous ciprofloxacin in seriously ill patients. Antimicrob Agents Chemother (1993) 7.05
Community-acquired pneumonia. N Engl J Med (1995) 6.12
Bacterial meningitis in the United States in 1995. Active Surveillance Team. N Engl J Med (1997) 5.73
Antimicrobial resistance of Streptococcus pneumoniae recovered from outpatients in the United States during the winter months of 1994 to 1995: results of a 30-center national surveillance study. Antimicrob Agents Chemother (1996) 5.68
Prognosis and outcomes of patients with community-acquired pneumonia. A meta-analysis. JAMA (1996) 5.31
Pharmacodynamics of levofloxacin: a new paradigm for early clinical trials. JAMA (1998) 4.99
Pharmacodynamics of a fluoroquinolone antimicrobial agent in a neutropenic rat model of Pseudomonas sepsis. Antimicrob Agents Chemother (1993) 4.76
Assessment of effects of protein binding on daptomycin and vancomycin killing of Staphylococcus aureus by using an in vitro pharmacodynamic model. Antimicrob Agents Chemother (1990) 3.36
Killing and regrowth of bacteria in vitro: a review. Scand J Infect Dis Suppl (1990) 2.53
Active efflux as a mechanism of resistance to ciprofloxacin in Streptococcus pneumoniae. Antimicrob Agents Chemother (1997) 2.50
Inappropriate use of oral ciprofloxacin. JAMA (1990) 2.27
Pneumococcal bacteremia during ciprofloxacin therapy for pneumococcal pneumonia. Am J Med (1989) 2.27
Antimicrobial resistance among lower respiratory tract isolates of Streptococcus pneumoniae: results of a 1992-93 western Europe and USA collaborative surveillance study. The Alexander Project Collaborative Group. J Antimicrob Chemother (1996) 2.21
A multicenter, randomized study comparing the efficacy and safety of intravenous and/or oral levofloxacin versus ceftriaxone and/or cefuroxime axetil in treatment of adults with community-acquired pneumonia. Antimicrob Agents Chemother (1997) 2.19
Infectious complications with respiratory pathogens despite ciprofloxacin therapy. N Engl J Med (1991) 2.12
Acute community-acquired sinusitis. Clin Infect Dis (1996) 1.97
Pharmacodynamics and pharmacokinetics of antibiotics with special reference to the fluoroquinolones. Am J Med (1991) 1.84
Pharmacokinetics of ampicillin-sulbactam in healthy elderly and young volunteers. Antimicrob Agents Chemother (1991) 1.19
Ciprofloxacin in the treatment of acute exacerbations of chronic bronchitis. Eur J Clin Microbiol (1986) 1.16
Induction of resistance of Streptococcus pneumoniae to quinolones in vitro. Chemotherapy (1993) 1.04
Single-dose pharmacokinetics of intravenous ampicillin plus sulbactam in healthy elderly and young adult subjects. J Antimicrob Chemother (1989) 1.01
Drug-resistant pneumococcal infections in the United States. A problem for clinicians, laboratories, and public health. JAMA (1994) 1.01
Pharmacokinetics of sulbactam/ampicillin in humans after intravenous and intramuscular injection. Chemotherapy (1990) 0.99
Quinolones in the treatment of bronchopulmonary infections. Rev Infect Dis (1988) 0.88
The failure of ciprofloxacin to prevent the progression of Streptococcus pneumoniae infections to meningitis. Mo Med (1991) 0.88
Pneumococcal meningitis during intravenous ciprofloxacin therapy. Am J Med (1990) 0.88
Comparative pharmacokinetics of sulbactam/ampicillin and clavulanic acid/amoxycillin in human volunteers. Drugs (1988) 0.87
Absorption of ciprofloxacin in patients with diabetic gastroparesis. Antimicrob Agents Chemother (1995) 0.83
An association between air pollution and mortality in six U.S. cities. N Engl J Med (1993) 38.84
Characterization of an avian influenza A (H5N1) virus isolated from a child with a fatal respiratory illness. Science (1998) 19.40
Interleukin-13: central mediator of allergic asthma. Science (1998) 14.05
Implementing a unified approach to family-based tests of association. Genet Epidemiol (2000) 10.96
The family based association test method: strategies for studying general genotype--phenotype associations. Eur J Hum Genet (2001) 9.09
Cell transformation by the superoxide-generating oxidase Mox1. Nature (1999) 6.23
Nonredundant roles of the mPer1 and mPer2 genes in the mammalian circadian clock. Cell (2001) 4.61
Structure of PAK1 in an autoinhibited conformation reveals a multistage activation switch. Cell (2000) 4.21
Pharmacokinetics and clinical use of cephalosporin antibiotics. J Pharm Sci (1975) 4.01
Homologs of gp91phox: cloning and tissue expression of Nox3, Nox4, and Nox5. Gene (2001) 3.97
Penetration of amoxicillin, cefaclor, erythromycin-sulfisoxazole, and trimethoprim-sulfamethoxazole into the middle ear fluid of patients with chronic serous otitis media. J Infect Dis (1982) 3.96
Conditional expression of fibroblast growth factor-7 in the developing and mature lung. J Biol Chem (2000) 3.95
Clinical, epidemiologic and bacteriologic observations of an outbreak of methicillin-resistant Staphylococcus aureus at a large community hospital. Am J Med (1976) 3.86
Functional interaction between InsP3 receptors and store-operated Htrp3 channels. Nature (1998) 3.68
Association between air pollution and low birth weight: a community-based study. Environ Health Perspect (1997) 3.32
Abnormal angiogenesis but intact hematopoietic potential in TGF-beta type I receptor-deficient mice. EMBO J (2001) 3.24
TGF-beta/Smad3 signals repress chondrocyte hypertrophic differentiation and are required for maintaining articular cartilage. J Cell Biol (2001) 3.22
FGFR-3 and FGFR-4 function cooperatively to direct alveogenesis in the murine lung. Development (1998) 3.21
Antifungal pharmacodynamic characteristics of fluconazole and amphotericin B tested against Candida albicans. Antimicrob Agents Chemother (1997) 3.17
Isolation of two new members of the NF-AT gene family and functional characterization of the NF-AT proteins. Immunity (1995) 3.07
Helicobacter pylori eradication in Western Australia using novel quadruple therapy combinations. Aliment Pharmacol Ther (2012) 2.94
Activity of minocycline against Acinetobacter calcoaceticus var. anitratus (syn. Herellea vaginicola) and Serratia marcescens. Antimicrob Agents Chemother (1975) 2.92
Actin filament disassembly is a sufficient final trigger for exocytosis in nonexcitable cells. J Cell Biol (1995) 2.90
Differential targeting of beta -adrenergic receptor subtypes and adenylyl cyclase to cardiomyocyte caveolae. A mechanism to functionally regulate the cAMP signaling pathway. J Biol Chem (2000) 2.86
The analysis of 51 genes in DSM-IV combined type attention deficit hyperactivity disorder: association signals in DRD4, DAT1 and 16 other genes. Mol Psychiatry (2006) 2.80
Antibody catalysis of the oxidation of water. Science (2001) 2.74
Regulation of vascular endothelial growth factor-dependent retinal neovascularization by insulin-like growth factor-1 receptor. Nat Med (1999) 2.74
Adhesion formation after previous caesarean section-a meta-analysis and systematic review. BJOG (2010) 2.66
Complete genome sequence of the shrimp white spot bacilliform virus. J Virol (2001) 2.58
Human beta-defensins. Cell Mol Life Sci (2006) 2.57
The tumor suppressor SMAD4/DPC4 is essential for epiblast proliferation and mesoderm induction in mice. Proc Natl Acad Sci U S A (1998) 2.51
E2F repression by C/EBPalpha is required for adipogenesis and granulopoiesis in vivo. Cell (2001) 2.50
Experience with a once-daily aminoglycoside program administered to 2,184 adult patients. Antimicrob Agents Chemother (1995) 2.49
The complete mitochondrial genome of the wallaroo (Macropus robustus) and the phylogenetic relationship among Monotremata, Marsupialia, and Eutheria. Proc Natl Acad Sci U S A (1997) 2.40
A targeted disruption of the murine Brca1 gene causes gamma-irradiation hypersensitivity and genetic instability. Oncogene (1998) 2.39
Association of genetic variation in FTO with risk of obesity and type 2 diabetes with data from 96,551 East and South Asians. Diabetologia (2011) 2.37
Patterns of condom use among adolescents: the impact of mother-adolescent communication. Am J Public Health (1998) 2.37
Polarized expression of Ca2+ channels in pancreatic and salivary gland cells. Correlation with initiation and propagation of [Ca2+]i waves. J Biol Chem (1997) 2.35
Molecular changes associated with the transmission of avian influenza a H5N1 and H9N2 viruses to humans. J Med Virol (2002) 2.35
Angiogenesis defects and mesenchymal apoptosis in mice lacking SMAD5. Development (1999) 2.34
Multiple genetic changes are associated with mammary tumorigenesis in Brca1 conditional knockout mice. Oncogene (2001) 2.33
CAKbeta/Pyk2 kinase is a signaling link for induction of long-term potentiation in CA1 hippocampus. Neuron (2001) 2.22
Reduced nitric oxide production and altered myocardial metabolism during the decompensation of pacing-induced heart failure in the conscious dog. Circ Res (1998) 2.16
The future of genetic case-control studies. Adv Genet (2001) 2.11
Separation of subcellular compartments containing distinct functional forms of MHC class II. J Cell Biol (1994) 2.09
A unified Haseman-Elston method for testing linkage with quantitative traits. Am J Hum Genet (2000) 2.08
Dietary phytoestrogens. Annu Rev Nutr (1997) 2.07
Synthesis of a novel hepatitis C virus protein by ribosomal frameshift. EMBO J (2001) 2.03
The p35/Cdk5 kinase is a neuron-specific Rac effector that inhibits Pak1 activity. Nature (1998) 2.01
Accumulation of defective viral genomes in peripheral blood mononuclear cells of human immunodeficiency virus type 1-infected individuals. J Virol (1997) 2.00
Substrate-induced magnetic ordering and switching of iron porphyrin molecules. Nat Mater (2007) 1.98
The relationship between opsin overexpression and photoreceptor degeneration. Invest Ophthalmol Vis Sci (2001) 1.98
Acquired cancer stem cell phenotypes through Oct4-mediated dedifferentiation. Oncogene (2012) 1.95
Failure of egg cylinder elongation and mesoderm induction in mouse embryos lacking the tumor suppressor smad2. Proc Natl Acad Sci U S A (1998) 1.94
Comparison of 10 influenza A (H1N1 and H3N2) haemagglutinin sequences obtained directly from clinical specimens to those of MDCK cell- and egg-grown viruses. J Gen Virol (1993) 1.92
The neuronal repressor REST/NRSF is an essential regulator in medulloblastoma cells. Nat Med (2000) 1.92
Sustained increases in CD4 cell counts in asymptomatic human immunodeficiency virus type 1-seropositive patients treated with prednisolone for 1 year. J Infect Dis (1995) 1.88
Risk factors for acute hepatitis B and its progression to chronic hepatitis in Shanghai, China. Gut (2008) 1.86
Identification of RIP3, a RIP-like kinase that activates apoptosis and NFkappaB. Curr Biol (1999) 1.85
Ablation of transplanted HTLV-I Tax-transformed tumors in mice by antisense inhibition of NF-kappa B. Science (1992) 1.85
Suppressed miR-424 expression via upregulation of target gene Chk1 contributes to the progression of cervical cancer. Oncogene (2012) 1.80
SC35 plays a role in T cell development and alternative splicing of CD45. Mol Cell (2001) 1.76
Effect of phosphorothioate modification of oligodeoxynucleotides on specific protein binding. J Biol Chem (1994) 1.76
Risk factors for oesophageal cancer in northeast China. Int J Cancer (1994) 1.73
Adherence to highly active antiretroviral therapy predicts virologic outcome at an inner-city human immunodeficiency virus clinic. Clin Infect Dis (2001) 1.72
Hematotoxicity among Chinese workers heavily exposed to benzene. Am J Ind Med (1996) 1.69
Comparison of bronchopulmonary pharmacokinetics of clarithromycin and azithromycin. Antimicrob Agents Chemother (1996) 1.68
Overwhelming sepsis associated with group A beta hemolytic streptococci. J Bone Joint Surg Am (1971) 1.66
An influenza A (H1N1) virus, closely related to swine influenza virus, responsible for a fatal case of human influenza. J Virol (1994) 1.65
Genetic diversity in the northernmost Oryza rufipogon populations estimated by SSR markers. Theor Appl Genet (2003) 1.65
Gram-negative bacillary meningitis. Am J Med (1975) 1.64
Development of meningitis during cephalothin therapy. Ann Intern Med (1973) 1.62
The Shp-2 tyrosine phosphatase has opposite effects in mediating the activation of extracellular signal-regulated and c-Jun NH2-terminal mitogen-activated protein kinases. J Biol Chem (1998) 1.62
Airway hyperresponsiveness to histamine associated with accelerated decline in FEV1. Am J Respir Crit Care Med (1995) 1.62
Crystal structure of the complex of the cyclin D-dependent kinase Cdk6 bound to the cell-cycle inhibitor p19INK4d. Nature (1998) 1.61
Late onset of renal and hepatic cysts in Pkd1-targeted heterozygotes. Nat Genet (1999) 1.61
Prospective study of exposure to environmental tobacco smoke and dysmenorrhea. Environ Health Perspect (2000) 1.60
Cardiovascular diseases: oxidative damage and antioxidant protection. Eur Rev Med Pharmacol Sci (2014) 1.59
A human PKD1 transgene generates functional polycystin-1 in mice and is associated with a cystic phenotype. Hum Mol Genet (2000) 1.58
Role of nitric oxide in the regulation of oxygen consumption in conscious dogs. Circ Res (1994) 1.57
Distribution of methicillin-resistant Staphylococcus aureus clones among health care facilities in Connecticut, New Jersey, and Pennsylvania. . Microb Drug Resist (2000) 1.57
Ethnic differences in the prevalence of the homozygous deleted genotype of glutathione S-transferase theta. Carcinogenesis (1995) 1.57
ACE inhibitors promote nitric oxide accumulation to modulate myocardial oxygen consumption. Circulation (1997) 1.56
SNPkit: an efficient approach to systematic evaluation of candidate single nucleotide polymorphisms in public databases. Biotechniques (2002) 1.55
Pharmacokinetics and pharmacodynamics of total and unbound cefoxitin and cefotetan in healthy volunteers. J Antimicrob Chemother (1989) 1.55
Synthesis and characterization of human alpha-defensins 4-6. J Pept Res (2004) 1.54
Benzene poisoning, a risk factor for hematological malignancy, is associated with the NQO1 609C-->T mutation and rapid fractional excretion of chlorzoxazone. Cancer Res (1997) 1.54
A Pro250Arg substitution in mouse Fgfr1 causes increased expression of Cbfa1 and premature fusion of calvarial sutures. Hum Mol Genet (2000) 1.53
Forensic palaeontology: The Archaeoraptor forgery. Nature (2001) 1.53
Bioefficacy of beta-carotene dissolved in oil studied in children in Indonesia. Am J Clin Nutr (2001) 1.52
Genetic susceptibility to benzene and shortened gestation: evidence of gene-environment interaction. Am J Epidemiol (2000) 1.52
In vivo expression of the novel CXC chemokine BRAK in normal and cancerous human tissue. Am J Pathol (2000) 1.51
The N-terminal domain of RGS4 confers receptor-selective inhibition of G protein signaling. J Biol Chem (1998) 1.51